The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site …

Sep 17, 2024 · Abstract Importance: The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. …

Jul 22, 2024 · These 2 randomized clinical trials compare the efficacy and safety of risankizumab vs placebo during an induction trial and a maintenance trial in patients with ulcerative colitis.

DOSING & MONITORING GUIDE INDICATIONS1 Crohn’s Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn’s disease in adults. Ulcerative Colitis: SKYRIZI is …

Jul 23, 2024 · Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulcers on the inner lining of the colon (large intestine).

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This approval …

Jun 20, 2024 · Ulcerative colitis patients may experience some serious side effects with Skyrizi, including severe allergic reactions, an increased risk of infections, and liver problems.

For the treatment of Crohn’s disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks). Interrupt treatment with SKYRIZI if drug-induced liver …

MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s Drug Agency (CDA-AMC) …

Nov 28, 2025 · SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel …